Advertisement
Imaging
Subscribe to Imaging
View Sample

FREE Email Newsletter

Interview with Elizabeth H. Blackburn, Ph.D.

November 9, 2010 5:34 am | by AACR | News | Comments

Prevention 2010: Interview with Elizabeth H. Blackburn, Ph.D., AACR president, 2009 Nobel Prize in Medicine or Physiology recipient, Morris Herzstein professor of biology and physiology in the department of biochemistry and biophysics at the University of California, San Francisco.

Arcadia Resources Announces Improved Fiscal 2011 Second Quarter Results

November 9, 2010 4:36 am | by Bio-Medicine.Org | News | Comments

INDIANAPOLIS, Nov. 9, 2010 /- Arcadia Resources, Inc. (NYSE Amex: KAD ), a leading provider of innovative consumer health care services under the Arcadia HealthCare(SM) brand, today announced fiscal 2011 second quarter net revenues of $25.8 million and a net loss of $2.9 million, or $0.02...

PAREXEL International to Participate in the Lazard Capital Markets Healthcare Conference in New York and the Jefferies Healthcare Summit in Boston

November 9, 2010 1:36 am | by Bio-Medicine.Org | News | Comments

BOSTON, Nov. 9, 2010 /- PAREXEL International Corporation (Nasdaq: PRXL ) announced today it will be presenting at the Lazard Capital Markets Healthcare Conference in New York.  Josef von Rickenbach, Chairman and Chief Executive Officer will be making a presentation on PAREXEL at...

Advertisement

China BCT Reschedules Conference Call to Discuss Third Quarter 2010 Results

November 9, 2010 1:35 am | by Bio-Medicine.Org | News | Comments

China BCT Reschedules Conference Call to Discuss Third Quarter 2010... -- LIUZHOU CITY, Guangxi, China, Nov. 9, 2010 /PRNewswire-Asia-FirstCall/ --

Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments

November 8, 2010 10:34 pm | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Nov. 9, 2010 /- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) today reported financial results for the third quarter ended September 30, 2010. Arena also reported earlier today top-line results from its lorcaserin Phase 3 BLOOM-DM (Behavioral modification and Lorcaserin for...

Intercell AG Announces Q3 2010 Results and Updates on R & D Progress and Management

November 8, 2010 10:33 pm | by Bio-Medicine.Org | News | Comments

VIENNA, Nov. 9, 2010 /- Today, Intercell AG (VSE: ICLL) announced its financial results for the third quarter of 2010 and presented an update on the Company's key R&D programs as well as changes to the Management Board. Financial Results IXIARO and JESPECT sales revenues continue...

Prevention 2010: Interview with Curtis C. Harris, M.D

November 8, 2010 1:38 pm | by AACR | News | Comments

Dr. Harris discusses the topic of his distinguished lecture, inflammation and cancer and the role of infection and chronic inflammation in cancer development.

2010 Prevention: Chemoprevention Teleconference Recording

November 8, 2010 1:38 pm | by AACR | News | Comments

Moderated by Scott Lippman, M.D., editor-in-chief of Cancer Prevention Research and professor and chair in the department of thoracic head and neck medical oncology at The University of Texas MD Anderson Cancer Center

Advertisement

BioStorage Technologies is Set for Expansion and Growth With the Appointment of Gregory Swanberg as Chief Executive Officer

November 8, 2010 7:33 am | by Bio-Medicine.Org | News | Comments

INDIANAPOLIS, Nov. 8, 2010 /- BioStorage Technologies, a global leader in sample management, cold chain logistics and biomaterial storage for the pharmaceutical and biotechnology industries, today announced that the company has appointed Gregory Swanberg to serve as chief executive...

Prevention 2010: Interview with John Carpten, Ph.D.

November 8, 2010 6:33 am | by AACR | News | Comments

In this audio interview, Dr. Carpten discusses the latest genetic technology that can be used for various tumors, the potential for new treatments for many types of cancer and the African-American Hereditary Prostate Cancer Study Network.

Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2011 Financial Results

November 8, 2010 3:35 am | by Bio-Medicine.Org | News | Comments

BETHESDA, Md., Nov. 8, 2010 /PRNewswire-Asia/ -- Chindex International, Inc. (Nasdaq: CHDX ), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced financial results for the second quarter and first half of...

Parascript Awarded $244,479.25 Affordable Care Act Grant From the U.S. Government

November 8, 2010 3:35 am | by Bio-Medicine.Org | News | Comments

LONGMONT, Colo., Nov. 8, 2010 /- Parascript, LLC, the image analysis and pattern recognition technology provider, today announced that it was awarded a cash grant of $244,479.25 under the U.S. Government's Affordable Care Act. Under this act, the therapeutic discovery project program...

Need Help Affording Your Meds? LegitScript Adds Patient Assistance Feature

November 7, 2010 10:32 pm | by Bio-Medicine.Org | News | Comments

PORTLAND, Oregon, Nov. 8, 2010 /- A leading Internet pharmacy verification service offers a new message for patients: There are ways to get affordable medicines without using unregulated, potentially dangerous "rogue" Internet pharmacies. LegitScript, a firm that monitors "rogue" Internet...

Advertisement

WuXi PharmaTech Awarded GLP Certificate from SFDA for Suzhou Toxicology Facility

November 7, 2010 10:32 pm | by Bio-Medicine.Org | News | Comments

SHANGHAI, Nov. 8, 2010 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX ), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it had been awarded a Certificate of Good...

Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent

November 7, 2010 8:35 pm | by Bio-Medicine.Org | News | Comments

RESEARCH TRIANGLE PARK, N.C., Nov. 7, 2010 /- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today reaffirmed its commitment to the dual development of CMX001 as a medical countermeasure against smallpox and as a broad-spectrum antiviral...

In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Ph...

November 7, 2010 4:33 pm | by Bio-Medicine.Org | News | Comments

NEW YORK, Nov. 7, 2010 /- Pfizer Inc. (NYSE: PFE ) today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically...

Medicare Policy Changes Will Make it More Difficult for Nevada Beneficiaries to Obtain Power Wheelchairs

November 5, 2010 12:35 pm | by Bio-Medicine.Org | News | Comments

RENO, Nev., Nov. 5, 2010 /PRNewswire-USNewswire/ -- Will power wheelchairs continue to be available to Nevada's Medicare patients following a series of federal regulatory and policy changes? There are grave concerns among consumer groups, Medicare beneficiaries and homecare equipment...

Dehaier Medical Wins $2 Million Distribution Bid for Rural Healthcare Construction Project

November 5, 2010 7:39 am | by Bio-Medicine.Org | News | Comments

BEIJING, Nov. 5, 2010 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM ) ("Dehaier" or the "Company"), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that it has won a...

SAFE IN COMMON Launches Global Injection Safety Website

November 5, 2010 7:39 am | by Bio-Medicine.Org | News | Comments

LEWISBERRY, Pa., Nov. 5, 2010 /- SAFE IN COMMON, an online community of  healthcare workers, educators, patients, community leaders and individuals, today announced the launch of its website dedicated to raising awareness of global injection safety challenges. SAFE IN COMMON's launch...

IntegenX Launches the Apollo 324 System for Automated DNA Library Preparation at the ASHG Meeting

November 5, 2010 7:39 am | by Bio-Medicine.Org | News | Comments

PLEASANTON, Calif., Nov. 5, 2010 /- IntegenX, Inc. (IXI) today at the 60th Annual American Society of Human Genetics Meeting announced the launch of their Apollo 324™ System, a benchtop robotic workstation that automates the construction of DNA fragment libraries for next-generation...

Varian Medical Systems Management to Present at Lazard Capital Markets 7th Annual Healthcare Conference

November 5, 2010 7:38 am | by Bio-Medicine.Org | News | Comments

PALO ALTO, Calif., Nov. 5, 2010 /- Varian Medical Systems (NYSE: VAR ) is scheduled to present at Lazard Capital Markets Healthcare Conference at 9:30 a.m. ET on Wednesday, November 17th at the St. Regis Hotel in New York City. Participating executives will include Elisha Finney, senior...

Business-to-Business Magazine Names Orion HealthCorp CEO as Top 25 Entrepreneur for 2010

November 4, 2010 7:34 am | by Bio-Medicine.Org | News | Comments

ATLANTA, Nov. 4, 2010 /- Orion HealthCorp , Inc., a leader in medical billing and practice management for more than 20 years, announced today that its President and CEO, Terrence L. Bauer, has been named to Business-to-Business Magazine's 2010 Top 25 Entrepreneur list. Bauer ranked No. 12...

SPO Announces Completion of Rebranding Program

November 4, 2010 7:34 am | by Bio-Medicine.Org | News | Comments

SPO Announces Completion of Rebranding Program -- NEW YORK, November 4, 2010 /-

Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results

November 4, 2010 3:35 am | by Bio-Medicine.Org | News | Comments

MISSISSAUGA, Ontario, Nov. 4, 2010 /- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) announces third quarter financial results for 2010. The merger of Biovail Corporation (Legacy Biovail) and Valeant Pharmaceuticals International (Legacy Valeant) was completed on...

Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan

November 4, 2010 3:34 am | by Bio-Medicine.Org | News | Comments

MISSISSAUGA, Ontario, Nov. 4, 2010 /- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) today announced that the Company's Board of Directors (the "Board") has declared a one-time special dividend of US$1.00 per common share (the "Special Dividend") that shareholders of...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading